Lymphoma - haematology - SA Health Approved Cancer Chemotherapy Protocol Register

Lymphoma

Lymphoma
Protocol Administration at chemotherapy unit level Review Date
Lymphoma brentuximab vedotin Medium August 2021
Lymphoma DHAP (dexamethasone cytarabine cISplatin) High August 2025
Lymphoma GDP (gemcitabine dexamethasone cISplatin) Medium February 2022
Lymphoma gemcitabine and vinORELBine Medium August 2024

Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma
Protocol Administration at chemotherapy unit level Review Date
Cutaneous T-cell lymphoma vorinostat Low August 2023
Lymphoma bendamustine and rituximab
Medium February 2022
NK T-Cell lymphoma DDGP (dexamethasone ciSplatin gemcitabine pegaspargase)3
High February 2022
NK T-Cell lymphoma SMILE (dexamethasone methotrexate IFOSFamide asparaginase etoposide) High August 2021
Non-Hodgkin lymphoma bendamustine and obinutuzumab Medium August 2022
Non-Hodgkin lymphoma chlorambucil and RITUximab Medium August 2024
Non-Hodgkin lymphoma CHOEP14 (CYCLOPHOSPHamide DOXOrubicin vinCRISTine etoposide prednisolone) High August 2024
Non-Hodgkin lymphoma CHOEP21 (CYCLOPHOSPHamide DOXOrubicin vinCRISTine etoposide prednisolone) High August 2024
Non-Hodgkin Lymphoma CHOP14 (CYCLOPHOSPHamide DOXOrubicin vincristine Prednisolone) Medium* (treatment must be provided under the supervision of a visiting/in-house haematologist) August 2024
Non-Hodgkin Lymphoma CHOP21 (CYCLOPHOSPHamide DOXOrubicin vincristine Prednisolone) Medium* (treatment must be provided under the supervision of a visiting/in-house haematologist)
August 2024
Non-Hodgkin lymphoma DA-R-EPOCH (dose adjusted RITUximab etoposide prednisolone vinCRISTine CYCLOPHOSPHamide DOXOrubicin) High August 2022
Non-Hodgkin lymphoma DHAC (dexamethasone cytarabine cARBOplatin) High August 2024
Non-Hodgkin lymphoma hyper CVAD part A High August 2022
Non-Hodgkin lymphoma hyper CVAD Part B High August 2022
Non-Hodgkin lymphoma ICE (fractionated IFOSFamide cARBOplatin etoposide) High August 2024
Non-Hodgkin lymphoma idelalisib Low August 2024
Non-Hodgkin lymphoma obinutuzumab maintenance Low August 2022
Non-Hodgkin lymphoma O-CHOP21 (obinutuzumab CYCLOPHOSPHamide DOXOrubicin vinCRISTine prednisolone) Medium August 2022
Non-Hodgkin lymphoma O-CVP (obinutuzumab CYCLOPHOSPHamide vinCRISTine prednisolone) Medium August 2022
Non-Hodgkin lymphoma polatuzumab vedotin, bendamustine and rituximab3
High August 2021
Non-Hodgkin lymphoma R-CHOEP14 (RITUximab CYCLOPHOSPHamide DOXOrubicin vinCRISTine etoposide prednisolone) High August 2024
Non-Hodgkin Lymphoma R-CHOP14 (RITUximab CYCLOPHOSPHamide DOXOrubicin vinCRISTine Prednisolone) Medium* (treatment must be provided under the supervision of a visiting/in-house haematologist)
August 2021
Non-Hodgkin lymphoma R-CHOP21  (RITUximab CYCLOPHOSPHamide DOXOrubicin vinCRISTine Prednisolone) Medium* (treatment must be provided under the supervision of a visiting/in-house haematologist)
August 2021
Non-Hodgkin Lymphoma R-CVP (RITUximab CYCLOPHOSPHamide vincristine Prednisolone) Medium* (treatment must be provided under the supervision of a visiting/in-house haematologist)
August 2024
Non-Hodgkin lymphoma R-DHAOx (RITUximab dexamethasone cytarabine oxaliplatin) High February 2022
Non-Hodgkin lymphoma R-DHAP (RITUximab dexamethasone cytarabine cISplatin) High August 2024 
Non-Hodgkin lymphoma R-GDP (rituximab gemcitabine dexamethasone ciSplatin)
Medium* (treatment must be provided under the supervision of a visiting/in-house haematologist)
August 2021
Non-Hodgkin lymphoma R-GemOX (RITUximab gemcitabine oxaliplatin) Medium* (treatment must be provided under the supervision of a visiting/in-house haematologist)
February 2025
Non-Hodgkin lymphoma RICE (RITUximab infusional IFOSFamide cARBOplatin etoposide) High August 2024
Non-Hodgkin lymphoma RITUximab Medium August 2024
Non-Hodgkin lymphoma RITUximab Maintenance Low - Medium August 2021
Non-Hodgkin lymphoma rituximab maintenance subcutaneous Low February 2022
Non-Hodgkin lymphoma R-MiniCHOP (RITUximab CYCLOPHOSPHamide DOXOrubicin vinCRISTine prednisolone) High August 2024
CNS prophylaxis of DLBCL, R-MTX (Rituximab, Methotrexate, Calcium Folinate) (for information on this protocol please contact the SA Health Cancer Drug Committee)  
High March 2023
Pembrolizumab (flat dosing) Low February 2021
Peripheral T-cell lymphoma pralatrexate Medium August 2021
Peripheral T-cell lymphoma romidepsin Medium August 2022

Hodgkin Lymphoma

Hodgkin Lymphoma
Protocol Administration at chemotherapy unit level Review Date
Hodgkin lymphoma ABVD (DOXOrubicin bleomycin vinBLASTine dacarbazine) advanced stage Medium  August 2024
Hodgkin lymphoma ABVD (DOXOrubicin bleomycin vinBLASTine dacarbazine) early stage Medium  August 2024
Hodgkin lymphoma BEACOPP escalated dose (bleomycin etoposide DOXOrubicin CYCLOPHOSPHamide vinCRISTine procarbazine prednisolone) High August 2020
Hodgkin lymphoma ChlVPP (chlorambucil vinBLASTine procarbazine prednisolone) Medium August 2022
Hodgkin lymphoma ICE (fractionated IFOSFamide cARBOplatin etoposide) High August 2024
Pembrolizumab (flat dosing) Low February 2021

Burkitt lymphoma

Burkitt lymphoma
Protocol Administration at chemotherapy unit level Review Date
Burkitt lymphoma dose modified CODOX-M (CYCLOPHOSPHamide vinCRISTine DOXOrubicin methotrexate) High February 2022
Burkitt lymphoma IVAC (IFOSFamide etoposide cytarabine) High February 2022

Mantle cell lymphoma

Mantle cell lymphoma
Protocol Administration at chemotherapy unit level Review Date
Mantle cell lymphoma ibrutinib Low August 2024
Mantle cell lymphoma R-BAC (rituximab, bendamustine, cytarabine)
High August 2021
Mantle cell lymphoma R-CHOP (RITUximab CYCLOPHOSPHamide DOXOrubicin vinCRISTine prednisolone) Medium* (treatment must be provided under the supervision of a visiting/in-house haematologist) August 2024
Mantle cell lymphoma R-DHAP (RITUximab dexamethasone cytarabine cISplatin) High August 2024
Mantle cell lymphoma R-HiDAC (RITUximab and cytarabine) High August 2024
Mantle cell lymphoma R-maxi-CHOP (RITUximab CYCLOPHOSPHamide DOXOrubicin vinCRISTine prednisolone) High August 2024

Primary CNS lymphoma

Primary CNS lymphoma
Protocol Administration at chemotherapy unit level Review Date
Primary CNS lymphoma (PCNSL) R-MPV/high dose cytarabine treatment overview High August 2024
Primary CNS lymphoma (PCNSL) R-MPV (RITUximab methotrexate procarbazine vinCRISTine ) - part 1 High August 2024
Primary CNS lymphoma (PCNSL) consolidation high dose cytarabine - part 2 High August 2024
Primary CNS lymphoma (PCNSL) MATRix (methotrexate cytarabine thiotepa and rituximab) High August 2022

Notes

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units 
  3. Non-formulary drug included in the protocol
  4. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.